
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is a globally-recognized healthcare company, with a strong presence in the less invasive medical device market, where it holds a significant 91% market share in the US. We anticipate a slight growth slowdown in WATCHMAN sales, but we remain positive on the company's broad portfolio, healthy profitability metrics, and new product development, leading us to maintain a Buy rating with a 12-month price target of $57 at a P/E multiple of 16.0x 2027E adjusted EPS.
Bears say
Boston Scientific is facing significant challenges ahead, as management has signaled slowing sales for its key product, WATCHMAN, and has had to lower their revenue guidance due to market share losses and weak performance in the Interventional Oncology and Embolization segment. Additionally, the recent acquisition of MiRus and investment in Penumbra raise concerns about the company's allocation of capital and ability to achieve strong returns for shareholders. With sentiment towards the stock turning negative and multiple competitors in the same space, it may be difficult for Boston Scientific to regain its market position and drive significant growth in the coming years.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares